Introduction: Non-union of the humeral shaft is a rare condition. In these patients, more stable fixation with or
Introduction
Although rare, non-union of the humerus is normally the result of inadequate fixation, such as use of a device that does not control rotation (typically a paediatric nail being used in adults), and the presence of specific aggravating complications (radial palsy) [1] . The humerus has two anatomical features that must be taken into account when planning treatment: the rotation must be fully controlled and the bone can be shortened. Fixation with two plates may be necessary to control rotation [2] . Adding a graft to fill a defect may not be relevant as the bone is not weight bearing. In cases of non-union, a corticocancellous autograft in combination with plate fixation appears to be the best treatment strategy [3] . Although treatment of humeral non-union is well defined, few studies have looked into failed non-union repair, resistant non-union cases and non-union cases where the biological environment is compromised [4] , [5] , [6] . The purpose of this study was to evaluate bone union following compassionate use of bone morphogenetic protein-7 (BMP7), an osteogenic growth factor, for treating humeral non-union.
Material and Methods

Patients
This was a single-centre, prospective, observational study without a control group during 4 consecutive years. Two types of patients had been treated with BMP7. One group consisted of patients with resistant non-union, meaning the non-union had not healed despite at least one specific treatment being carried out for this non-union (at least two procedures performed prior to BMP7 application). The other group consisted of patients at high-risk of nonunion, meaning fractures with a high risk of not healing because of local factors (open fracture) or systemic factors (smoker, diabetic, non-union in another location); these fractures had progressed to non-union but had specifically been treated for non-union (only one procedure-fracture fixation-performed before BMP7 application). In all cases the non union and the bone defect were located at the medium third of the humerus shaft.
Patients were included if they had a resistant or highrisk diaphyseal or metaphyseal humeral non-union that had been present for at least 6 months. The case series consisted of 16 patients with an average age of 49 years (24-71) who had a resistant or high-risk non-union (Table  1 ). They were treated and then followed prospectively. The final evaluation was performed by a surgeon who was not involved in the procedures or patient care. The initial fracture was located in the mid-shaft in 11 cases, upper shaft in one case, and distal shaft in three cases and was supracondylar in one case. Four patients had accompanying radial palsy, one had brachial plexus involvement and three had open fractures. One patient had non-fusion of an elbow arthrodesis that had been performed because of post-traumatic osteoarthritis. Initially, three fractures had been operated with retrograde pinning, two with a non-locked intramedullary (IM) nail, and two with locked IM nail, one with a cast, seven with a single plate and one with an external fixator. Seven of these initial constructs were deemed unstable. Two patients presented with non-union of another bone at the time of the humerus fracture. Two patients were diabetic, two were confirmed smokers with more than 20 pack-years, and one smoked about 10 pack-years. These 16 fractures had not healed after 9 months. Nine were re-operated at least once using a standard technique (new fixation device, decortication, corticocancellous bone graft or intramedullary reaming) before the BMP7 procedure. The BMP7 procedure was the first surgical procedure for the other seven patients.
At the time the BMP7 was added, the fracture symptoms had been present for 24.4 months (5-103) and an average of 1.9 procedures (1-6) had been performed. Four patients had already received a bone graft and one had received biphasic calcium phosphate cement. There were 12 cases of atrophic non-union, 1 of eutrophic non-union, 2 of hypertrophic non-union and 1 of non-union with a 3 cm bone defect. Two of the non-union cases were considered septic without fistula (Staphylococcus epidermidis, Staphylococcus aureus) and one was considered septic with fistula (no samples collected). In every patient, the existing fixation device was removed and replaced with standard or locking plates, and then BMP7 was added. Upon re-operation with the addition of BMP7, 4 of the 16 patients also received an iliac crest autograft because the surgeon determined the resulting limb shortening was unsightly. Fracture union was determined by an independent observer using A/P and lateral radiographs, with CT scans being consulted if radiographic findings were ambiguous. Union was defined as the presence of two cortices in the two perpendicular planes, thus four intact cortices.
Technique
BMP7 (also known as Osteogenic Protein-1, OP-1) is a protein that promotes bone formation by inducing differentiation of mesenchymal stems recruited to the implantation site from the bone marrow, periosteum and muscle. Once bound to cell surface receptors, it triggers a cascade of cellular events leading to the formation of chondroblasts and osteoblasts. The commercially available form of BMP7 (Osigraft®, Stryker/Olympus) contains 3.5 mg of recombinant human OP-1 (eptotermin alfa) as the active ingredient and bovine collagen as a resorbable carrier. Each vial contains 1 g of powder. Each vial of Osigraft® is reconstituted with 2 to 3 ml of sterile 9 mg/ml sodium chloride solution (0.9% w/v) prior to use. Eptotermin alpha protein is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. Bovine collagen is derived from diaphyseal bone and consists mainly of type I collagen. The European marketing authorization for Osigraft® is for treatment of tibial non-union of at least 9 months duration, secondary to trauma, in skeletally mature patients, in cases where previous treatment with autograft has failed or autograft use is not feasible. Osigraft® is contraindicated in children and adolescents (less than 18 years old) and skeletally immature patients [7] .
Osigraft
® implantation
In this case series, any septic or necrotic tissues were resected, the medullary canal was reamed and the surrounding bone was decorticated. The existing fixation was evaluated and modified as needed, and in some cases completely revised (addition of second plate or removal of nail and replacement with plate). A bone graft was added if warranted by the local conditions observed during the procedure, even if no bone defect was present. The Osigraft® was implanted by mixing it with blood or bone marrow at the end of the procedure, before wound closure. When reconstituted, Osigraft® has the consistency of wet sand; this facilitates its implantation and placement at the bone-graft site. If no graft was added to the nonunion gap, Osigraft® was placed in the medullary canal. A haemostatic compress was placed around the non-union site for drainage.
Results
All patients were reviewed after at least 24 months of follow-up (Table 2) . No neurological complications occurred, but one patient was under treatment at a regional pain centre for chronic pain. Union was achieved in 15 of the 16 cases (93.7% union rate); there was one failure. The average time to union was 12.75 months. In the 16 cases where rhBMP7 was combined with a change in the fixation device, union was obtained in 15 of them. In 5 of these 15 cases, changing the fixation method increased the stability of the fracture site. Union was achieved in three of the four cases where autograft was also used. The infection resolved in the three cases of septic non-union and union occurred in two of these cases after rhBMP7 addition.
The only failure was in a 59 years-old male with a eutrophic, septic non-union complicated by radial palsy following a Cauchoix type 2 open fractures of the upper third of the humerus, which had already undergone four prior procedures, including bone grafting. A bone defect was present after his infection site underwent debridement; this defect was then treated with the induced membrane technique. BMP7 was added during the second phase of this technique, in combination with an iliac crest autograft. On day 10, this patient's wound showed signs of pruritus and erythema but no signs of infection. The episode resolved spontaneously 7 days later without systemic or local treatment. This skin condition was highly suggestive an allergic reaction, likely related to rhBMP7. However, there is no proof of an allergic reaction to rhBMP7 because no samples were collected for laboratory analysis. In the month after the procedure, the patient spent 3 weeks building a shed and the two plates broke after 8 months.
In the 15 patients where the fracture had healed, shoulder abduction and forward flexion were 97% and 92% of the other side. The elbow's flexion-extension range was 126°, which was 89% of the contralateral side in the 14 patients with a mobile elbow. The worst functional outcomes were in a patient with type I regional pain syndrome (Figures 1 to 3 ). 
Discussion
Limitations
Although our series of patients was followed prospectively, only a small number of patients were included and there was no control group. However, this is the case for most studies on humeral non-union. Another limitation was the inclusion of cases treated on a compassionate use basis, making the patient population heterogeneous. Our definition of radiological union (4 cortices) was different than the one typically used in published studies in this area (3 cortices).
Treatments used for humeral non-union
The incidence of non-union in the humeral shaft varies between 15% and 30%. This is slightly higher than in other long bones; these fractures are rare and inadequate fixation methods are still frequently being used [8] . Half of the patients in our study had undergone initial fracture fixation with retrograde pinning or a non-locked nail. Treatment of humeral non-union must take into consideration both the mechanical and biological environment, as with other long bones. However, the humerus is different because it is not a weight bearing bone; it undergoes rotational loading and may be shortened by several centimetres if a bone defect is present. To improve stability, the existing fixation method may need to be revised or completely replaced by an altogether different device.
Three types of fixation methods have been described in published studies: plates (standard or locking), intramedullary nails (with or without reaming) and external fixator [3] . The union rate was between 90 and 100% in studies where plate fixation was used. A series of 30 cases of diaphyseal humeral non-union, mainly in the middle-third and initially fixed by pinning, was reported by Segonds, Alnot and Masmejean [1] . All cases were re-operated and treated by plating and cancellous bone autograft. Union was achieved in all cases in 4 months. Half the cases experienced improved shoulder and elbow function. There were two cases of transient radial nerve contusions. If intraoperative stability is insufficient, a second plate can be added [3] , [9] . If the fracture was initially pinned, it may not be sufficient to simply ream the medullary canal and change out the fixation device. In some studies with fewer than 30 patients [10] , [11] , [12] , the union rate was below 50% when the revision of the non-union was fixed with percutaneous nailing, without grafting. Although reaming seems to play a biological role, it cannot compensate for insufficient rotational stability. In other IM nailing studies, addition of an autograft improved the union rate, despite the need for an open procedure. External fixators are used because of theoretical advantages related to bone union, but their application in the upper limb has several disadvantages.
The union rate varies as a function of the fixation . However, the addition of a bone graft was a confounding factor in the study: it was used in 95% of cases in the plate fixation cases, 79% of the nail fixation cases and 41% of external fixation cases. The Kontakis study also highlighted the complications related to the various types of fixation methods. There were more nerve-related complications when an external fixator was used (9%) relative to a plate (5%) or IM nail (3%) and there were more infections with the external fixator (60% pin infections, including benign and more severe cases) relative to plate (2%) or IM nail (4%) fixation. Complications associated with autograft harvesting were reported only in the studies where plate fixation had been used; the complication rate was 5.6% for the 352 cases evaluated.
Resistant and high-risk humeral non-union
Although several publications describe the use of different fixation methods for humeral non-union, very few have addressed cases of resistant non-union. In the resistant non-union cases, the search for more stable fixation is slowly gaining traction for optimisation of graft vascularisation.
Ring et al. [13] described a series of older patients (average age of 62 years) where two-thirds of patients had already undergone one surgical procedure. Use of a standard or locking, long (11-hole) or shaped plate with 6.5 mm cancellous bone screws in combination with autograft resulted in bone union in 91% of cases. In a series of resistant and sometime extreme cases of non-union (multiple recurrences), Kaminski et al. [14] reported that use of vascularised cortical-periosteal grafts harvested from the supracondylar section of the femur resulted in union after 6 to 11 months.
Although addition of an autograft in humeral non-union cases is not justified from a structural standpoint, it has been carried out by several surgical teams [3] . The main advantage of using autograft is that it provides three biological players (matrix, cells, and growth factors) in undefined, yet balanced amounts. Autograft contains 40% bone fragments larger than 100 microns; these fragments may contain bone progenitor cells [15] . This type of graft must not be washed. For non-union cases, some studies have shown that fewer progenitor cells are present in the bone marrow [16] and lower levels of certain circulating growth factors such as TGF-beta1 [17] .
Unfortunately, few authors report the complication rate or donor-site complications in studies where autograft was harvested. In the Kontakis study [3] , complications associated with autograft harvesting were reported only in studies where plate fixation had been used; the complication rate was 5.6% in the 352 cases evaluated. The donor site complication rate was 44% in the Hierholzer study [2] .
In cases of resistant non-union after failed repair attempt with autograft, and because of donor site complications, some teams have used growth factors. Hierholzer et al. [2] reported a retrospective study where an iliac cancellous bone autograft (45 patients) was compared to demineralized bone matrix (DBM) for the treatment of humeral non-union. The time between the fracture event and surgery was 14 months in the autograft group and 22 months in the DBM group. In both groups, it was the first failure and fixation was carried out with a plate. The union rate was similar in both groups, but iatrogenic complications related to autograft harvesting led the authors to recommend using DBM. Several studies with BMP7 have been published, but these do not include a control group (Table 3) . Four humeral non-union studies have been published and they reported high union rates [18] , [19] , [20] , [21] . However, the cases were not well described and no control group was included.
When our study is compared to published studies, our study is the first to describe growth factor treatment of resistant non-unions of the humerus. Hierholzer et al. [2] used growth factors (within the DBM), but not in cases of resistant non-union. This makes it difficult to compare our results with published results. The sample size (n = 16) in the current study is similar to other published studies that included a relatively small number of cases. When comparing our study to studies where a different biological substance (autograft, vascularised graft, DBM) was added, there is little difference in the union rates. The evaluation of functional outcomes (range of motion) in this study sets it apart from other published studies.
Use of BMPs in long bone non-union
Published studies on use of BMP in non-union cases are limited and difficult to compare to each other. Two types of studies have been performed: case series of resistant non-union with and without bone defects, and randomised controlled trials.
Case series
These are single cases or case series of non-union, mainly in the tibia and femur, which have not resolved despite one or two surgical procedures. These cases either had large bone defects or were considered tight (stable) non-union with small defects (1 cm) [22] , [23] , [24] , [25] , [26] . Unfortunately, it is often difficult to determine if a bone defect existed in a particular case. Moreover, in some of the cases, BMP was used as a last resort before amputation. No control groups were included.
Two technical points make it challenging to analyse these studies. 1) The BMP is not added alone, thus it is difficult to attribute the procedure's success to the BMP. A carrier such as autograft or allograft is typically added. 2) In the absence of a true bone defect, it is quite difficult to follow the progression of bone healing on radiographs. Analysis of CT scans would have been helpful in this scenario.
Although the reported cases are dissimilar, two elements were emphasized by the authors: stable fixation and good soft tissue coverage. The BMP was always combined with a synthetic or bone carrier, then the BMP and carrier were placed within the resected non-union site. In a report of compassionate use in patients who had previously undergone multiple surgical procedures, addition of BMP resulted in rapid bone union (6 months) [27] . All of the published studies on long bone non-unions were performed with BMP7. Addition of BMP with a massive cancellous bone autograft is now being evaluated (induced membrane technique).
Randomised, comparative trials
Two such studies have been published: one study relates to open leg fractures with addition of BMP2 [28] and the other relates to tibial non-union cases treated with BMP7 [29] . In the subgroup of fractures where BMP2 was used, the results were the same as when the fracture site was reamed. In the non-union study where autograft was compared to BMP7, the patients in the BMP group had unfavourable characteristics (larger bone defects, higher number of smokers) but the results were not inferior to autograft. Although neither study showed BMP to be superior, the BMPs outcomes were similar to outcomes with autograft application, and there were significantly fewer cases of postoperative sepsis in the BMP groups. Specific adverse effects were rare and related mainly to local ossification [29] . Although there is a large body of basic research on the link between BMPs and cancer, which is a logical relationship given the ubiquitous nature of these growth factors, no cases of BMP-related cancer have been reported [30] , [31] .
Conclusion
At one point, orthopaedic surgeons and hurried readers believed that the problem of diaphyseal non-union was solved when bone growth inducers appeared on the market. They extrapolated the results of animal studies and applied them to their future patients. But in most cases, these animals had healthy bone, and had not undergone multiple surgical procedures and did not smoke. Moreover, the readers did not look at the time to union, which was always on the order of months. Even when the defect was made in a healthy bone, union required more than 1 year. Now, and given our experience with resistant humeral non-unions (at least one failed autograft treatment) and high-risk non-unions (open fracture, palsy complication, systemic risk factors), use of BMP7 while following the standard non-union management principles shows that further procedures are unnecessary. The positive effect on bone union is even more consistent when the nonunion is in the cortex, fixation is stable, the BMP is added to the medullary canal, and the patient is compliant. Since either bone marrow cells or bone inductive proteins can be used, it is important to carefully analyse past failures and successes, while attempting to assign each player their role in the bone union game. It is also important to respect well known, but sometimes forgotten, principles for managing long bone non-union. Rigour is more important than ever when designing and evaluating future studies. Currently the RhBMP7 is no longer available.
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